The role of the ALK receptor in cancer biology

Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs

(2016) Richard Bayliss et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib

(2016) Sandeep Kodityal et al.   LUNG CANCER

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

(2016) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Zebrafish Leucocyte tyrosine kinase controls iridophore establishment, proliferation and survival

(2016) Andrey Fadeev et al.   Pigment Cell & Melanoma Research

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib

(2015) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine

(2015) R. Katayama et al.   CLINICAL CANCER RESEARCH

Signaling from Glia and Cholinergic Neurons Controls Nutrient-Dependent Production of an Insulin-like Peptide for Drosophila Body Growth

(2015) Naoki Okamoto et al.   DEVELOPMENTAL CELL

Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non–small-cell Lung Cancer Exhibiting Resistance to Ceritinib

(2015) Gouji Toyokawa et al.   Journal of Thoracic Oncology

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

(2015) Thomas F Eleveld et al.   NATURE GENETICS

Targeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic Hypogonadism

(2015) Barbara Witek et al.   PLoS One

Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand–receptor interactions

(2015) Andrey V. Reshetnyak et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dynamics-Driven Allostery in Protein Kinases

(2015) Alexandr P. Kornev et al.   TRENDS IN BIOCHEMICAL SCIENCES

Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors

(2015) C. Voena et al.   Cancer Immunology Research

Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma

(2015) Alex Cazes et al.   Oncotarget

Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma

(2015) Nathan F. Moore et al.   Oncotarget

ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma

(2014) Scott C. Bresler et al.   CANCER CELL

Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib

(2014) R. Katayama et al.   CLINICAL CANCER RESEARCH

Intragenic anaplastic lymphoma kinase (ALK) rearrangements: Translocations as a novel mechanism ofALKactivation in neuroblastoma tumors

(2014) Susanne Fransson et al.   GENES CHROMOSOMES & CANCER

Emergence of New ALK Mutations at Relapse of Neuroblastoma

(2014) Gudrun Schleiermacher et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations

(2014) Ted W. Johnson et al.   JOURNAL OF MEDICINAL CHEMISTRY

Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib

(2014) Sai-Hong Ignatius Ou et al.   Journal of Thoracic Oncology

A Nice Problem to Have: When ALK Inhibitor Therapy Works Better Than Expected

(2014) Robert C. Doebele   Journal of Thoracic Oncology

A Novel Fusion of TPR and ALK in Lung Adenocarcinoma

(2014) Yoon-La Choi et al.   Journal of Thoracic Oncology

HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib

(2014) Douglas D. Fang et al.   Journal of Thoracic Oncology

Identification of a Novel HIP1-ALK Fusion Variant in Non–Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged NSCLC Patients with Resistance to Alectinib

(2014) Sai-Hong Ignatius Ou et al.   Journal of Thoracic Oncology

HIP1–ALK, a Novel Fusion Protein Identified in Lung Adenocarcinoma

(2014) Mineui Hong et al.   Journal of Thoracic Oncology

The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non-Small Cell Lung Cancer Model Mice

(2014) M. Mori et al.   MOLECULAR CANCER THERAPEUTICS

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Deorphanization of the human leukocyte tyrosine kinase (LTK) receptor by a signaling screen of the extracellular proteome

(2014) H. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma

(2014) G. Umapathy et al.   Science Signaling

The Neuroblastoma ALK(I1250T) Mutation Is a Kinase-Dead RTK In Vitro and In Vivo

(2014) Christina Schönherr et al.   Translational Oncology

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

(2014) L. Friboulet et al.   Cancer Discovery

Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK-mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma

(2013) S. R. P. McDonnell et al.   BLOOD

Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy inALK-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance

(2013) Zhao Chen et al.   CLINICAL CANCER RESEARCH

Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells

(2013) Kamaraj Sattu et al.   FEBS Journal

NovelTRAF1-ALKfusion identified by deep RNA sequencing of anaplastic large cell lymphoma

(2013) Andrew L. Feldman et al.   GENES CHROMOSOMES & CANCER

Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

(2013) Justin F. Gainor et al.   JOURNAL OF CLINICAL ONCOLOGY

ALKin Lung Cancer: Past, Present, and Future

(2013) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials

(2013) Thomas H. Marsilje et al.   JOURNAL OF MEDICINAL CHEMISTRY

Identification of recurrentFGFR3fusion genes in lung cancer through kinome-centred RNA sequencing

(2013) Ian J Majewski et al.   JOURNAL OF PATHOLOGY

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

(2013) Yael P Mossé et al.   LANCET ONCOLOGY

Anaplastic Lymphoma Kinase Is Required for Neurogenesis in the Developing Central Nervous System of Zebrafish

(2013) Sheng Yao et al.   PLoS One

MicroRNA 96 Is a Post-Transcriptional Suppressor of Anaplastic Lymphoma Kinase Expression

(2012) Deeksha Vishwamitra et al.   AMERICAN JOURNAL OF PATHOLOGY

The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma

(2012) Teeara Berry et al.   CANCER CELL

Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis

(2012) Shizhen Zhu et al.   CANCER CELL

Characterization of Rearrangements Involving the ALK Gene Reveals a Novel Truncated Form Associated with Tumor Aggressiveness in Neuroblastoma

(2012) A. Cazes et al.   CANCER RESEARCH

Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer

(2012) Robert C. Doebele et al.   CLINICAL CANCER RESEARCH

Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma

(2012) D. Chand et al.   Disease Models & Mechanisms

Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing

(2012) Yeonjoo Jung et al.   GENES CHROMOSOMES & CANCER

Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma

(2012) E L Carpenter et al.   ONCOGENE

Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma

(2012) J Okubo et al.   ONCOGENE

Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells

(2012) C Schönherr et al.   ONCOGENE

KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only

(2012) Yuki Togashi et al.   PLoS One

Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684

(2011) Christina Schönherr et al.   BIOCHEMICAL JOURNAL

MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression

(2011) C. Desjobert et al.   BLOOD

miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma

(2011) H. Matsuyama et al.   BLOOD

CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant

(2011) Hiroshi Sakamoto et al.   CANCER CELL

Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene

(2011) A. K. Murugan et al.   CANCER RESEARCH

Anaplastic Lymphoma Kinase Spares Organ Growth during Nutrient Restriction in Drosophila

(2011) Louise Y. Cheng et al.   CELL

ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

(2011) J. M. Heuckmann et al.   CLINICAL CANCER RESEARCH

The Nucleophosmin-Anaplastic Lymphoma Kinase Oncogene Interacts, Activates, and Uses the Kinase PIKfyve to Increase Invasiveness

(2011) Sophie Dupuis-Coronas et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas

(2011) E Dejean et al.   LEUKEMIA

The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking

(2011) P Mazot et al.   ONCOGENE

Anaplastic Lymphoma Kinase and Leukocyte Tyrosine Kinase: Functions and genetic interactions in learning, memory and adult neurogenesis

(2011) Joseph B. Weiss et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

An Evolutionary Conserved Role for Anaplastic Lymphoma Kinase in Behavioral Responses to Ethanol

(2011) Amy W. Lasek et al.   PLoS One

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK

(2011) R. Katayama et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Receptor Tyrosine Kinase Alk Controls Neurofibromin Functions in Drosophila Growth and Learning

(2011) Jean Y. Gouzi et al.   PLoS Genetics

Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain

(2010) Christian C. Lee et al.   BIOCHEMICAL JOURNAL

Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors

(2010) Roberto T. Bossi et al.   BIOCHEMISTRY

Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene

(2010) Z. Chen et al.   CANCER RESEARCH

Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy

(2010) T. Martinsson et al.   CANCER RESEARCH

Anterograde Jelly belly ligand to Alk receptor signaling at developing synapses is regulated by Mind the gap

(2010) J. Rohrbough et al.   DEVELOPMENT

The biology and treatment of EML4-ALK non-small cell lung cancer

(2010) Takaaki Sasaki et al.   EUROPEAN JOURNAL OF CANCER

The Tyrosine 343 Residue of Nucleophosmin (NPM)-Anaplastic Lymphoma Kinase (ALK) Is Important for Its Interaction with SHP1, a Cytoplasmic Tyrosine Phosphatase with Tumor Suppressor Functions

(2010) Samar A. Hegazy et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Crizotinib — Latest Champion in the Cancer Wars?

(2010) Bengt Hallberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor

(2010) James E. Butrynski et al.   NEW ENGLAND JOURNAL OF MEDICINE

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oncogenic kinase NPM/ALK induces expression of HIF1α mRNA

(2010) M Marzec et al.   ONCOGENE

Proteome-Wide Identification of Novel Binding Partners to the Oncogenic Fusion Gene Protein, NPM-ALK, using Tandem Affinity Purification and Mass Spectrometry

(2009) Fang Wu et al.   AMERICAN JOURNAL OF PATHOLOGY

Defining the conserved internal architecture of a protein kinase

(2009) Alexandr P. Kornev et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer

(2009) K. Takeuchi et al.   CLINICAL CANCER RESEARCH

High incidence of DNA mutations and gene amplifications of theALKgene in advanced sporadic neuroblastoma tumours

(2008) Helena Carén et al.   BIOCHEMICAL JOURNAL

The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation

(2008) Chiara Ambrogio et al.   CANCER RESEARCH

C. elegans Anaplastic Lymphoma Kinase Ortholog SCD-2 Controls Dauer Formation by Modulating TGF-β Signaling

(2008) David J. Reiner et al.   CURRENT BIOLOGY

Identification of ALK as a major familial neuroblastoma predisposition gene

(2008) Yaël P. Mossé et al.   NATURE

Activating mutations in ALK provide a therapeutic target in neuroblastoma

(2008) Rani E. George et al.   NATURE

Oncogenic mutations of ALK kinase in neuroblastoma

(2008) Yuyan Chen et al.   NATURE

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

(2008) Isabelle Janoueix-Lerosey et al.   NATURE

The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination

(2008) Roberto Chiarle et al.   NATURE MEDICINE

A mouse model for EML4-ALK-positive lung cancer

(2008) M. Soda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Leukocyte Tyrosine Kinase Functions in Pigment Cell Development

(2008) Susana S. Lopes et al.   PLoS Genetics